Opinion

Video

Reflections on 2024’s Progress in R/R CLL

Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world evidence for newer agents, and emerging combination strategies, while expressing optimism for future advances in personalized therapy approaches and novel drug development.

Related Videos
4 experts are featured in this series.
1 expert in this video
5 experts are featured in this series
1 expert in this video
5 experts are featured in this series
4 experts are featured in this series.
Raj Chovatiya, MD, PhD, MSCI.
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo